What is the prognosis of fibrillary glomerulonephritis?

Prognosis of Fibrillary Glomerulonephritis

Fibrillary glomerulonephritis has a poor prognosis, with approximately 40-52% of patients progressing to end-stage renal disease (ESRD) within 2-4 years of diagnosis, and complete or partial remission occurring in only 13-30% of cases.

Key Prognostic Outcomes

The most recent and comprehensive evidence demonstrates consistently poor outcomes across multiple cohorts:

• ESRD progression: 44-52% of patients reach ESRD during follow-up 1, 2, 3, 4
• Median time to ESRD: Approximately 2-4 years from diagnosis 5
• Remission rates: Only 13-30% achieve complete or partial remission 1, 2
• Rapid progression: 33% require renal replacement therapy within 12 months of diagnosis 3
• Transplant recurrence: Disease recurs in 36% of kidney transplant recipients 1

Independent Predictors of Poor Outcome

Based on multivariate analysis, the following factors predict progression to ESRD:

Strong Predictors

• Older age at diagnosis 1
• Higher serum creatinine at biopsy 1
• Greater proteinuria at presentation (particularly >3500 mg/g) 1, 4
• Higher percentage of global glomerulosclerosis 1
• Female sex 4
• Diffuse proliferative GN pattern on histology 4
• Hypoalbuminemia <3 g/dL (HR 6.52, p=0.04) 2
• Lower baseline hemoglobin 6

Potential Biomarker

• Serum C3 ≤134 mg/dL may indicate worse prognosis (30.8% kidney survival vs 87.5% with C3 >134 mg/dL), though multivariate models have not definitively confirmed this association 6

Clinical Presentation at Diagnosis

Understanding baseline characteristics helps contextualize prognosis:

• Universal proteinuria (100% of patients) 1
• Nephrotic-range proteinuria: 38-58% of cases 1, 4
• Renal dysfunction at presentation: 66-91% 1, 4
• Median eGFR at biopsy: 29 mL/min/1.73m² 3
• Hematuria: 52% 1
• Hypertension: 71% 1

Associated Conditions Affecting Prognosis

FGN frequently coexists with conditions that may influence outcomes:

• Malignancy (solid organ or hematological): 20-23% 1, 4
• Autoimmune diseases: 15-28.5% 1, 4
• Diabetes mellitus: 34.2% 4
• Dysproteinemia/plasma cell disorders: 17% 1

Critical caveat: When FGN occurs secondary to plasma cell neoplasms, treatment of the underlying malignancy with anti-myeloma therapies may result in significant improvement in kidney function 5. This represents a rare but important exception to the generally poor prognosis.

Response to Treatment

Despite various immunosuppressive approaches, outcomes remain disappointing:

• Partial remission with rituximab: 30.8% in one cohort, all within the exclusive rituximab group 2
• No statistically significant impact of immunosuppression on overall outcomes in most studies 3, 4
• Rituximab association with non-progression: Observed but not reaching statistical significance 4
• Mortality and ESRD combined: 38.4-51% during follow-up 2, 4

Histopathological Patterns

The most common patterns (which influence prognosis):

1. Mesangial proliferative/sclerosing GN (most common) 1, 6
2. Membranoproliferative GN 1
3. Diffuse proliferative GN (associated with worse outcomes) 4

Important note: Atypical histopathological features (congophilia, light-chain restriction, IgG negativity) occur in approximately 16% of cases, complicating differential diagnosis but not clearly altering prognosis 6.

Quality of Life Considerations

Beyond mortality and ESRD, patients face significant morbidity:

• High burden of nephrotic syndrome complications (edema, thromboembolism risk, infections)
• Rapid decline in kidney function requiring early dialysis planning
• Substantial treatment-related toxicity from immunosuppression without clear benefit
• High risk of disease recurrence post-transplant, affecting transplant candidacy decisions

Clinical Algorithm for Prognostication

At diagnosis, assess:

1. Age (older = worse)
2. Serum creatinine and eGFR (higher creatinine = worse)
3. Degree of proteinuria (>3500 mg/g = worse)
4. Serum albumin (<3 g/dL = worse)
5. Hemoglobin level (lower = worse)
6. Histological pattern (diffuse proliferative = worse)
7. Percentage of global glomerulosclerosis (higher = worse)
8. Screen for underlying malignancy, especially plasma cell disorders

Patients with multiple poor prognostic factors should be counseled about the high likelihood (>50%) of progression to ESRD within 2-4 years, regardless of immunosuppressive therapy.